Benralizumab 30 mg vs placebo
Rate of severe exacerbations requiring hospitalisation Eosinophils ≥ 220/μL · patients with chronic obstructive pulmonary disease
Benralizumab 30 mg showed no clear difference in rate of severe exacerbations requiring hospitalisation Eosinophils ≥… compared with placebo (moderate certainty).
1 finding from 1 review
- Anti‐IL‐5 therapies for chronic obstructive pulmonary disease 2020 · Cochrane Headline outcomes onlyRate ratio 0.96 [0.75, 1.22]2 studies · 1523 participantsModerate